Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
29 06 2021
Historique:
received: 07 12 2020
revised: 26 04 2021
accepted: 21 05 2021
pubmed: 7 6 2021
medline: 29 6 2021
entrez: 6 6 2021
Statut: ppublish

Résumé

Current detergent or ether-disrupted split vaccines (SVs) for influenza do not always induce adequate immune responses, especially in young children. This contrasts with the whole virus particle vaccines (WPVs) originally used against influenza that were immunogenic in both adults and children but were replaced by SV in the 1970s due to concerns with reactogenicity. In this study, we re-evaluated the immunogenicity of WPV and SV, prepared from the same batch of purified influenza virus, in cynomolgus macaques and confirmed that WPV is superior to SV in priming potency. In addition, we compared the ability of WPV and SV to induce innate immune responses, including the maturation of dendritic cells (DCs) in vitro. WPV stimulated greater production of inflammatory cytokines and type-I interferon in immune cells from mice and macaques compared to SV. Since these innate responses are likely triggered by the activation of pattern recognition receptors (PRRs) by viral RNA, the quantity and quality of viral RNA in each vaccine were assessed. Although the quantity of viral RNA was similar in the two vaccines, the amount of viral RNA of a length that can be recognized by PRRs was over 100-fold greater in WPV than in SV. More importantly, 1000-fold more viral RNA was delivered to DCs by WPV than by SV when exposed to preparations containing the same amount of HA protein. Furthermore, WPV induced up-regulation of the DC maturation marker CD86 on murine DCs, while SV did not. The present results suggest that the activation of antigen-presenting DCs, by PRR-recognizable viral RNA contained in WPV is responsible for the effective priming potency of WPV observed in naïve mice and macaques. WPV is thus recommended as an alternative option for seasonal influenza vaccines, especially for children.

Identifiants

pubmed: 34090697
pii: S0264-410X(21)00660-5
doi: 10.1016/j.vaccine.2021.05.065
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Influenza Vaccines 0
RNA, Viral 0
Vaccines, Inactivated 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3940-3951

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Masashi Shingai (M)

International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Naoki Nomura (N)

International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Toshiki Sekiya (T)

International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Marumi Ohno (M)

International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Daisuke Fujikura (D)

International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Chimuka Handabile (C)

International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Ryosuke Omori (R)

International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Yuki Ohara (Y)

KM Biologics Co. Ltd, Kumamoto, Japan.

Tomohiro Nishimura (T)

KM Biologics Co. Ltd, Kumamoto, Japan.

Masafumi Endo (M)

KM Biologics Co. Ltd, Kumamoto, Japan.

Kazuhiko Kimachi (K)

KM Biologics Co. Ltd, Kumamoto, Japan.

Ryotarou Mitsumata (R)

Denka Co., Ltd, Niigata, Japan.

Tomio Ikeda (T)

Denka Co., Ltd, Niigata, Japan.

Hiroki Kitayama (H)

BIKEN Co., Ltd, Kannonji, Japan.

Hironori Hatanaka (H)

BIKEN Co., Ltd, Kannonji, Japan.

Tomoyoshi Sobue (T)

Daiichi Sankyo, Co, Ltd, Tokyo, Japan.

Fumihito Muro (F)

Daiichi Sankyo, Co, Ltd, Tokyo, Japan.

Saori Suzuki (S)

Division of Pathgenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.

Cong Thanh Nguyen (C)

Division of Pathgenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.

Hirohito Ishigaki (H)

Division of Pathgenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.

Misako Nakayama (M)

Division of Pathgenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.

Yuya Mori (Y)

Division of Pathgenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.

Yasushi Itoh (Y)

Division of Pathgenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.

Marios Koutsakos (M)

International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Brendon Y Chua (BY)

International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Katherine Kedzierska (K)

International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Lorena E Brown (LE)

International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

David C Jackson (DC)

International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Kazumasa Ogasawara (K)

Division of Pathgenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.

Yoichiro Kino (Y)

Kino Consulting, Kumamoto, Japan.

Hiroshi Kida (H)

International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Collaborating Research Center for the Control of Infectious Diseases, Nagasaki University, Nagasaki, Japan. Electronic address: kida@vetmed.hokudai.ac.jp.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH